Multiplex Assays Market Forecasts to 2030 – Global Analysis By Product (Instruments, Consumables and Software & Services), Type (Protein Based Multiplex Assays, Nucleic Acid Multiplex Assays and Cell-based Multiplex Assays), Technology, Application, End U

Multiplex Assays Market Forecasts to 2030 – Global Analysis By Product (Instruments, Consumables and Software & Services), Type (Protein Based Multiplex Assays, Nucleic Acid Multiplex Assays and Cell-based Multiplex Assays), Technology, Application, End User and By Geography

According to Stratistics MRC, the Global Multiplex Assays Market is accounted for $3.8 billion in 2023 and is expected to reach $7.9 billion by 2030 growing at a CAGR of 10.8% during the forecast period. A multiplex assay is a lab technique that measures several analytes, such as proteins, nucleic acids, or other molecules, simultaneously in a single biological sample. This lab technique is widely used in many areas of biology, medicine, and diagnostics and enables researchers to extract more information from a single sample. Hospitals, clinical laboratories, research facilities, and pharmaceutical and biotechnological companies all frequently use the multiplex assay technique.

According to the report published by WHO in July 2023, each year there are an estimated 374 million new infections with 1 of 4 curable, more than 500 million people 15–49 years of age are estimated to have a genital infection with herpes simplex virus (HSV or herpes).

Market Dynamics:

Driver:

Advances in multiplex assay technologies

Multiplex assays have revolutionized research and diagnosis, such as PCR and immunoassays. These innovative methods save time and money by identifying numerous analytes in a single sample. Antibodies are used in immunoassays to identify and quantify target analytes. With multiplex immunoassays, numerous biomarkers, cytokines, or analytes are assessed in a single sample. This enhances knowledge of illness while saving time and money. Fluorescently tagged primers and probes may amplify and detect multiple target sequences in a single reaction, enabling high-throughput screening of multiple analytes.

Restraint:

High cost

The initial investment in multiplex assay equipment is high. Despite long-term savings and advantages, the initial investment costs may restrain the small-scale use of multiplex assays to a certain extent. The variable costs of the reagents needed and those fixed by the suppliers thereof add to the overall expenditure. Furthermore, maintenance and insurance, laboratory supervision, and overhead costs (including utilities, space, and administration) are also additional expenses. As a result, high instrument costs are a major factor limiting the wider adoption of multiplex assays.

Opportunity:

Expansion of the pharmaceutical and biotechnology industries

The growth of the multiplex assay market has been significantly fuelled by the expansion of the pharmaceutical and biotechnology industries. Advanced diagnostic tools play a critical role in supporting research, drug development, and clinical applications in these industries. Moreover, because multiplex assays allow for the simultaneous analysis of multiple biomarkers in a single sample, they are essential to both fields. Multiplex assays are becoming more and more essential in a variety of biotechnology and pharmaceutical applications due to this capability.

Threat:

Data security concerns

Data security concerns pose significant risks to the multiplex assay market. The risk of unauthorised access, breaches, or misuse is elevated due to the sensitive nature of the clinical and biological data used in multiplex assessments. Stringent data protection regulations in the healthcare and research sectors require robust cyber security measures. The potential harm to research and patient data hinders market acceptance and erodes confidence among stakeholders. Thus, market growth is hampered.

Covid-19 Impact

The market has been greatly and positively impacted by COVID-19. Multiplex assays, such as the SARS-CoV-2 assay, were used to diagnose COVID during this pandemic phase. During the pandemic, the demand for multiplex assays skyrocketed as healthcare systems worldwide scrambled to expand testing capabilities and improve efficiency. The FDA has granted approval to a number of companies, which has further paved the way for the market's expansion. During the pandemic, multiplex assay manufacturers have introduced a number of assays, which has increased the market's growth rate.

The flow cytometry segment is expected to be the largest during the forecast period

The flow cytometry segment is estimated to hold the largest share. Flow cytometry provides major advantages in terms of speed, sensitivity, and accuracy and allows for the simultaneous analysis of multiple parameters at the single-cell level. The flow cytometry segment is a leading technology in the market because of its capacity to generate large amounts of data and offer high-throughput analysis. Customers are more likely to choose devices like flow cytometry that can deliver thorough and dependable results due to the rising demand for personalized medicine and precise disease diagnosis. In the upcoming years, the multiplex assay market is anticipated to grow at the fastest rate in the flow cytometry segment.

The research & development segment is expected to have the highest CAGR during the forecast period

The research & development segment is anticipated to have lucrative growth during the forecast period Multiplex assays are frequently used in research settings to shed light on intricate biological processes, illness mechanisms, and medication development. The research and development sector is a market leader because it can supply important data for scientific investigations and pharmaceutical innovations. Customers are increasingly willing to invest in research and development projects that can result in novel treatments due to the rising incidence of complex diseases and the demand for cutting-edge therapeutic solutions. In the multiplex assay market, the research and development segment is anticipated to grow at the quickest rate.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to the high rate of adoption of multiplex assay goods and services as well as the notable rise in capital income in developed nations. The region's access to recently released goods and sophisticated healthcare systems also contribute to the market's expansion. Additionally, the market is expanding due to the presence of major players, R&D facilities, high levels of medical tourism, and strong purchasing power.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, due to the rise in the number of people with infectious and chronic illnesses, the growing awareness of the benefits of using multiplex assay goods and services, and the rising purchasing power of highly populated nations like China and India. Additionally, the region's market is growing because of things like new major players entering the market, rising per capita spending, and more government initiatives to improve the region's healthcare infrastructure.

Key players in the market

Some of the key players in the Multiplex Assays Market include Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers, Danaher Corporation, Hoffmann-La Roche, Biomerieux, Bio-Rad Laboratories, Sekisui Medical, Buhlmann Laboratories, Randox Laboratories, Merck Sharp & Dohme Corp, Illumina Inc, Qiagen, Abcam plc, Agilent Technologies and Meso Scale Diagnostics LLC.

Key Developments:

In July 2023, QIAGEN announced that the expansion of its digital PCR (dPCR) offering for the development of cell and gene therapies in the biopharma industry.

In June 2023, Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, announced that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A., a Warsaw, Poland, based developer of the PCR ONE technology for rapid, automated detection of infections via highly multiplexed PCR assays.

Products Covered:
• Instruments
• Consumables
• Software & Services

Types Covered:
• Protein Based Multiplex Assays
• Nucleic Acid Multiplex Assays
• Cell-based Multiplex Assays

Technologies Covered:
• Luminescence
• Flow Cytometry
• Multiplex Real-Time PCR
• Fluorescence Detection
• Other Technologies

Applications Covered:
• Research & Development
• Clinical Diagnostics

End Users Covered:
• Hospitals & Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Academic Institutes
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements